🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

KI postdoc Malte Roerden is pitching in for Stefani Spranger this afternoon, sharing his lab's work on exploring the relationships between strong and weak neoantigens in eliciting immune responses in clonal and subclonal tumors. #KIsymposium

I had a great time at my first professional symposium today with the Koch Institute at MIT. It was especially neat to see the lab I am working with this summer be represented by an excellent presentation from Malte Roerden.

QS ranks MIT the world’s number 1 university for 2023-24. This is the 12th year in a row for MIT, the Institute also places first in 11 subject areas. tinyurl.com/mvfy4v27 and tinyurl.com/y8dybjsc #ThisisMIT

“We may be close to a new revolution of cancer vaccines.” If you missed our Cancer Vaccines symposium this summer, we’ve got you covered. Video of the panel and presentations at the link. news.mit.edu/2023/snapshot-…

Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2: buff.ly/3QnwKnp Stefani Spranger MIT Biology #Immunology

Having a great time hearing about the latest in cancer immunotherapy research at #SITC2023 in San Diego and very happy to receive a Young Investigator Award! Come meet me at my poster (#929) if you‘re interested in how neoantigen architectures enable immune evasion!

We are hiring at multiple levels to join our team jstarklab.com MIT Dept of BE Koch Institute at MIT Apply below! Postdoc: tinyurl.com/3nufr3rp Lab Coordinator: tinyurl.com/3rhjvdf3 Tech: tinyurl.com/wud3hp6k Please repost! #immunoengineering #synbio #glycotime #newPI

🚨👇🏻A fantastically creative approach for solving the challenge of safely enhancing T cell potency for adoptive immunotherapy. Amazing work from ⁦Jaehyuk Choi⁩ and ⁦Kole Roybal⁩. nature.com/articles/s4158…

Combining tumor-targeting antibodies with IL-2 mRNA induces rejection of MHC class I-deficient tumors otherwise resistant to immune-, chemo-, and radiotherapy Cancer Cell cell.com/cancer-cell/fu…

Ludwig Massachusetts Institute of Technology (MIT)'s @StefaniSpranger chaired a session at #AACR2024 on the crosstalk between various myeloid cells & T cells in tumors & lymph nodes. She also shared her lab's findings on how dendritic cells shape cytotoxic T cell responses & are themselves influenced by other T cells.

Low doses of MHC-II-restricted neoantigen peptides induce cytotoxic Tr1 CD4 T cells that kill cDC1 and suppress cancer immunotherapy, which can be overcome by LILRB4 blockade, CD8-directed IL-2 mutein, or targeted loss of cDC2/monocytes nature nature.com/articles/s4158…

Thank you Journal for ImmunoTherapy of Cancer for the nice summary of our latest project where we studied how different neoantigen expression patterns impact anti-tumor immunity 👇

Check out the recent #JITC Editor Pick from Malte Roerden et al, "Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression" bit.ly/4gWP5SE

Very excited to share our recent work now published in Nature Rev Immunol! We reviewed how immune evasion mechanisms interfere with immunoediting to fosters intratumor heterogeneity (ITH) and discuss data on the role of ITH itself in blunting anti-tumor immunity. Stefani Spranger

How different immune evasion mechanisms interfere with immunoediting of evolving tumors - Malte Roerden Stefani Spranger Nature Rev Immunol oncodaily.com/url/218440 #Cancer #ImmuneOnc #IO #ImmunoOncology #Immunotherapy #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Looking forward to the visit!

Meet the Author: Malte Roerden (Malte Roerden), a physician-scientist from Koch Institute at MIT, is 1st author of “Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression,” recently published in #JITC! 1/6

Excited to share our review that’s now out in Science Immunology. We describe how DC-T cell interactions in lymph nodes specify CD8+ T cell fates and sustain anti-tumour immune responses. Stefani Spranger Koch Institute at MIT | science.org/doi/10.1126/sc…